Eli Lilly Reports Positive Phase 3 Results for Jaypirca Combo in CLL

Eli Lilly and Company (NYSE:LLY) announced positive results from the Phase 3 BRUIN CLL-322 clinical trial, which evaluated the addition of Jaypirca (pirtobrutinib) to a time-limited venetoclax and rituximab regimen for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

The Product

Jaypirca (pirtobrutinib) is a non-covalent BTK inhibitor administered orally, used to treat certain blood cancers. In this trial, it was added to a standard regimen for relapsed CLL patients.

Pricing and Availability

Eli Lilly has not yet disclosed pricing or commercial availability details for Jaypirca in this indication. The company is expected to submit the trial data to regulators for approval of the new indication.

Competition

Jaypirca competes with other BTK inhibitors such as ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa). Its non-covalent mechanism may offer efficacy in cases where other BTK inhibitors have failed.

Potential Impact on the Company

If approved for this indication, Jaypirca could strengthen Eli Lilly's hematology oncology portfolio and support revenue growth. This development is positive for LLY stock, particularly as the company focuses on expanding its pipeline.